Background: Rheumatoid Arthritis (RA) is associated to subclinical atherosclerosis. Traditional risk factors for cardiovascular outcomes do not explain completely the higher risk, which could be caused by chronic systemic inflammation. Objectives: The aim of this study is to relate abnormal carotid intima-media thickness (CIMT) to the presence of cardiovascular risk factors. Methods: Observational cross-section design. We included patients who fulfilled the 1987 ACR and/or 2010 ACR/EULAR classification criteria for RA, 40 to 75 years old, with no personal history of atherosclerotic CV disease. A board-certified radiologist performed carotid duplex ultrasounds. Patients were distributed in two groups according to the absence (Group 1) or presence (Group 2) of traditional risk factors for cardiovascular disease (smoking status, dyslipidemia, high blood pressure and diabetes). Results: A total of 82 patients were included. Demographic characteristics for each group are shown in Table 1 . Ultrasound findings are shown in Table 2 . CIMT alterations were more common in Group 2 (66.7%) than in Group 1 (38.7%), with statistical significance (p=0.013). Presence of carotid plaque was more common in Group 2 (27.5%) than in Group 1 (16.1%), shown clinical relevance, although did not shown statistical significance (p=0.18). Background: Interleukin-17 (IL-17) and IL-17-induced CC-chemokine ligand 20 (CCL20) are increasingly implicated in the pathogenesis of rheumatoid arthritis (RA). A correlation has been reported to exist between serum levels of IL-17 and CCL20 and the disease activity following biologic treatment [1] . However, such an effect has not been universally demonstrated [2] . Objectives: The aim of the present study was to investigate if serum IL-17 and CCL20 reflect activity of the disease and whether they could be of prognostic value for predicting therapeutic response to biologic therapy in RA. Methods: Thirty RA patients qualified to receive biologic treatment were prospectively assessed before and 12 weeks of therapy with either TNFα inhibitors or anti-IL-6 receptor antibodies. Serum concentrations of IL-17 and CCL20 were measured with high sensitivity ELISA with estimated detection levels 0.01 pg/ml and 0.47 pg/ml, respectively. Successful response to therapy was defined by the EULAR criteria. Results: The patient baseline characteristics were summarized in Table 1 . Twelve weeks of biologic treatment resulted in a significant improvement in the majority of the patients with only 2 patients (7%) identified as non-responders. The favorable response to therapy was reflected both by clinical and standard biochemical criteria (Table 2) . However, the mean serum concentrations of IL-17 and CCL20 did not change significantly over the course of therapy and they did not correlate with the disease activity, response to therapy, the type of biologic intervention and other medication used. 
